Diethylpropion

Summary

Diethylpropion (CHEMBL1194666) is an approved small-molecule appetite depressant (ATC A08AA03); indicated across 1 condition including obesity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A08AA03
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 205.3 Da · C13H19NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1194666
Name	Diethylpropion
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	7029
ChEBI	CHEBI:4530
ATC	A08AA03
Molecular formula	C13H19NO
Molecular weight	205.3
InChIKey	XXEPPPIWZFICOJ-UHFFFAOYSA-N

SMILES: CCN(CC)C(C)C(=O)C1=CC=CC=C1

IUPAC name: 2-(diethylamino)-1-phenylpropan-1-one

ChEBI definition: An aromatic ketone that is propiophenone in which one of the hydrogens α- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.

Pharmacological roles (ChEBI): appetite depressant.

Also known as: .alpha.-benzoyltriethylamine, Amfepramone, Anfepramona, Anfepramone, Anferpramon, C06954, D07444, Diethylcathinone, Diethylpropion, J4.327C, diethylpropion, DIETHYLPROPION

Parent form; salt/anhydrous children: CHEMBL1693

Patent coverage: 3,105 distinct patent families (12,073 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Progesterone receptor, 5-hydroxytryptamine receptor 2A, Histamine H1 receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	6.66	AC50	220	nM	CHEMBL_ACT_25192993
ADRA2A	5.35	AC50	4456	nM	CHEMBL_ACT_25156114
KCNH2	5.19	AC50	6504	nM	CHEMBL_ACT_25118837
HTR2A	5.12	AC50	7620	nM	CHEMBL_ACT_25173835

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00115063	PHASE4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT05756764	Not specified	ACTIVE_NOT_RECRUITING	Anti-obesity Pharmacotherapy and Inflammation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).